Details for Patent: 7,129,232
✉ Email this page to a colleague
Which drugs does patent 7,129,232 protect, and when does it expire?
Patent 7,129,232 protects ZERBAXA and is included in one NDA.
This patent has twenty-five patent family members in twenty countries.
Summary for Patent: 7,129,232
| Title: | Cephem compounds |
| Abstract: | The present invention relates to a compound of the formula [I]: ##STR00001## wherein R.sup.1 is lower alkyl, hydroxy(lower)alkyl or halo(lower)alkyl, and R.sup.2 is hydrogen or amino protecting group, or R.sup.1 and R.sup.2 are bonded together and form lower alkylene or lower alkenylene; R.sup.3 is hydrogen or lower alkyl; R.sup.4 is ##STR00002## R.sup.5 is carboxy or protected carboxy; and R.sup.6 is amino or protected amino, or a pharmaceutically acceptable salt thereof, a process for preparing a compound of the formula [I], and a pharmaceutical composition comprising a compound of the formula [I] in admixture with a pharmaceutically acceptable carrier. |
| Inventor(s): | Ohki; Hidenori (Osaka, JP), Okuda; Shinya (Osaka, JP), Yamanaka; Toshio (Osaka, JP), Ohgaki; Masaru (Osaka, JP), Toda; Ayako (Osaka, JP), Kawabata; Kohji (Osaka, JP), Inoue; Satoshi (Takata-gun, JP), Misumi; Keiji (Takata-gun, JP), Itoh; Kenji (Takata-gun, JP), Satoh; Kenji (Takata-gun, JP) |
| Assignee: | Astellas Pharma Inc. (Tokyo, JP) Wakunaga Pharmaceutical Co., Ltd (Osaka, JP) |
| Application Number: | 10/695,895 |
|
Patent Claim Types: see list of patent claims | Compound; Process; Composition; Use; |
Drugs Protected by US Patent 7,129,232
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cubist Pharms Llc | ZERBAXA | ceftolozane sulfate; tazobactam sodium | POWDER;INTRAVENOUS | 206829-001 | Dec 19, 2014 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | METHODS OF TREATING BACTERIAL ILLNESSES | ⤷ Try a Trial | ||
| Cubist Pharms Llc | ZERBAXA | ceftolozane sulfate; tazobactam sodium | POWDER;INTRAVENOUS | 206829-001 | Dec 19, 2014 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | METHODS FOR TREATING BACTERIAL INFECTIONS | ⤷ Try a Trial | ||
| Cubist Pharms Llc | ZERBAXA | ceftolozane sulfate; tazobactam sodium | POWDER;INTRAVENOUS | 206829-001 | Dec 19, 2014 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OLD) | ⤷ Try a Trial | ||
| Cubist Pharms Llc | ZERBAXA | ceftolozane sulfate; tazobactam sodium | POWDER;INTRAVENOUS | 206829-001 | Dec 19, 2014 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), USED IN COMBINATION WITH METRONIDAZOLE, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE) | ⤷ Try a Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 7,129,232
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Australia | 2002952355 | Oct 30, 2002 |
| Australia | 2003904813 | Sep 4, 2003 |
International Family Members for US Patent 7,129,232
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 041729 | ⤷ Try a Trial | |||
| Austria | 368042 | ⤷ Try a Trial | |||
| Australia | 2003274754 | ⤷ Try a Trial | |||
| Brazil | 0315188 | ⤷ Try a Trial | |||
| Brazil | PI0315188 | ⤷ Try a Trial | |||
| Canada | 2504730 | ⤷ Try a Trial | |||
| China | 100343260 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
